Literature DB >> 29532710

Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.

Masahiro Ueki1, Ichiro Kobayashi1,2, Shunichiro Takezaki1, Yusuke Tozawa1, Yuka Okura2, Masafumi Yamada1, Masataka Kuwana3, Tadashi Ariga1.   

Abstract

OBJECTIVES: The aim of our study is to clarify the association of myositis-specific autoantibodies (MSAs) with clinical and laboratory features in Japanese patients with juvenile idiopathic inflammatory myopathies (JIIMs).
METHODS: We retrospectively analyzed the frequency of MSAs and their association with clinical or laboratory findings in 25 Japanese patients with JIIMs in Hokkaido district.
RESULTS: Eighteen of the 25 patients (72%) were positive for MSAs; seven with anti-melanoma differentiation associated gene (MDA) 5 (28%), five with anti-transcriptional intermediary factor (TIF)-1γ (20%), four with anti-MJ/nuclear matrix protein (NXP)-2 (16%), two with anti-Jo-1 (8%), one with anti- HMG-CoA reductase, one with anti-signal recognition peptide (SRP) antibodies (4% each), including co-existence and transition of MSAs in one patient each. Anti-MDA5 antibodies were related to interstitial lung disease (ILD) and arthritis but not to amyopathic juvenile dermatomyositis. Drug-free remission was achieved, once ILD was overcome in this group. Anti-TIF-1γ antibodies were associated with typical rashes and mild myositis. Anti-MJ/NXP2 and anti-SRP antibodies were associated with severe muscle weakness. No patient was complicated with malignancy.
CONCLUSION: Anti-MDA5 antibodies are prevalent and closely associated with ILD in our series compared with other countries. There was no apparent difference in clinical features associated with other MSAs among races.

Entities:  

Keywords:  Juvenile idiopathic inflammatory myopathies; myositis-specific autoantibody

Mesh:

Substances:

Year:  2018        PMID: 29532710     DOI: 10.1080/14397595.2018.1452353

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

Review 1.  Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.

Authors:  Liubing Li; Chenxi Liu; Linlin Cheng; Songxin Yan; Haizhen Chen; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2020-07-17       Impact factor: 2.980

2.  Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.

Authors:  Gulnara Mamyrova; Takayuki Kishi; Min Shi; Ira N Targoff; Adam M Huber; Rodolfo V Curiel; Frederick W Miller; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

3.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

4.  Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.

Authors:  Xinning Wang; Yuchuan Ding; Zhixuan Zhou; Jun Hou; Yingjie Xu; Jianguo Li
Journal:  Pediatr Rheumatol Online J       Date:  2021-01-06       Impact factor: 3.054

5.  Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients.

Authors:  Anne Schänzer; Leonie Rager; Iris Dahlhaus; Carsten Dittmayer; Corinna Preusse; Adela Della Marina; Hans-Hilmar Goebel; Andreas Hahn; Werner Stenzel
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

Review 6.  Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.

Authors:  Renske G Kamperman; Anneke J van der Kooi; Marianne de Visser; Eleonora Aronica; Joost Raaphorst
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.